This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kandasamy, K. Articles by Srivastava, R. K. Search for Related Content PubMed PubMed Citation Articles by Kandasamy, K. Articles by Srivastava, R. K.

Role of the Phosphatidylinositol 3'-Kinase/PTEN/Akt Kinase Pathway in Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Non-Small Cell Lung Cancer Cells

Department of Pharmaceutical Sciences, University of Maryland- School of Pharmacy, Greenebaum Cancer Center, Baltimore, Maryland 21201-1180

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/APO-2L is a member of the TNF superfamily and has been shown to have selective antitumor activity. We here show that TRAIL does not induce apoptosis in some non-small cell lung cancer (NSCLC) cells. These cells are resistant to TRAIL because of the phosphatidylinositol 3'-kinase (PI3-K)-dependent activation of Akt/protein kinase B. The expression of phospho-Akt varies at the functional level but not at the mRNA level in NSCLC cells. Akt induces cell survival in NSCLC cells by blocking the Bid cleavage, upstream of cytochrome c release in the mitochondrial-dependent apoptotic pathway. The use of PI3-K inhibitors, Wortmannin or LY-294002, down-regulates the active Akt and reverses cellular resistance to TRAIL. In addition, genetically altering Akt expression by transfecting dominant negative Akt, sensitizes NSCLC cells to TRAIL. Conversely, transfection of constitutively active Akt into cells that express low, constitutively active Akt, increases TRAIL resistance. Alternate to this approach, transfection with PTEN, a lipid phosphatase, promotes sensitivity to TRAIL, whereas a PTEN mutant (PTEN-G129E) at the catalytic site is inactive in dephosphorylating active Akt. Furthermore, the loss of PTEN activity or overexpression of PI3-K-dependent Akt/protein kinase B activity promotes the survival of NSCLC cells. Modulation of Akt activity by combining pharmacological drugs or genetic alterations of the Akt expression induces cellular responsiveness to TRAIL. Thus, TRAIL can be used to treat NSCLC-resistant cells when combined with agents that down-regulate Akt activity.

This article has been cited by other articles:

				H.-L. CHANG, Y. SUGIMOTO, S. LIU, L.-S. WANG, Y.-W. HUANG, W. YE, and Y. C. LIN Keratinocyte Growth Factor (KGF) Regulates Estrogen Receptor-{alpha} (ER-{alpha}) Expression and Cell Apoptosis via Phosphatidylinositol 3-kinase (PI3K)/Akt Pathway in Human Breast Cancer Cells Anticancer Res, August 1, 2009; 29(8): 3195 - 3205. [Abstract] [Full Text] [PDF]

				S. Shankar, R. Davis, K. P. Singh, R. Kurzrock, D. D. Ross, and R. K. Srivastava Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice Mol. Cancer Ther., June 1, 2009; 8(6): 1596 - 1605. [Abstract] [Full Text] [PDF]

				S. Shankar, S. Ganapathy, and R. K. Srivastava Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis Clin. Cancer Res., November 1, 2008; 14(21): 6855 - 6866. [Abstract] [Full Text] [PDF]

				M. Kim, J. Liao, M. L. Dowling, K. R. Voong, S. E. Parker, S. Wang, W. S. El-Deiry, and G. D. Kao TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells Cancer Res., May 1, 2008; 68(9): 3440 - 3449. [Abstract] [Full Text] [PDF]

				C.-Y. Jin, D.-O. Moon, J.-D. Lee, M.-S. Heo, Y. H. Choi, C.-M. Lee, Y.-M. Park, and G.-Y. Kim Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells Carcinogenesis, May 1, 2007; 28(5): 1058 - 1066. [Abstract] [Full Text] [PDF]

				T. F. Gajewski On the TRAIL Toward Death Receptor-Based Cancer Therapeutics J. Clin. Oncol., April 10, 2007; 25(11): 1305 - 1307. [Full Text] [PDF]

				S. Corbacioglu, M. Kilic, M.-A. Westhoff, D. Reinhardt, S. Fulda, and K.-M. Debatin Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin Blood, November 15, 2006; 108(10): 3504 - 3513. [Abstract] [Full Text] [PDF]

				Y. Huang, N. Erdmann, H. Peng, S. Herek, J. S. Davis, X. Luo, T. Ikezu, and J. Zheng TRAIL-Mediated Apoptosis in HIV-1-Infected Macrophages Is Dependent on the Inhibition of Akt-1 Phosphorylation J. Immunol., August 15, 2006; 177(4): 2304 - 2313. [Abstract] [Full Text] [PDF]

				S. M Dougherty, W. Mazhawidza, A. R Bohn, K. A Robinson, K. A Mattingly, K. A Blankenship, M. O Huff, W. G McGregor, and C. M Klinge Gender difference in the activity but not expression of estrogen receptors {alpha} and {beta} in human lung adenocarcinoma cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 113 - 134. [Abstract] [Full Text] [PDF]

				J. C. Coffey, J. H. Wang, M. J. F. Smith, A. Laing, D. Bouchier-Hayes, T. G. Cotter, and H. P. Redmond Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced Apoptosis: NOVEL ROLE FOR AN OLD ENEMY J. Biol. Chem., June 3, 2005; 280(22): 20968 - 20977. [Abstract] [Full Text] [PDF]

				A. Shah, W. A. Swain, D. Richardson, J. Edwards, D. J. Stewart, C. M. Richardson, D. E.B. Swinson, D. Patel, J. L. Jones, and K. J. O'Byrne Phospho-Akt Expression Is Associated with a Favorable Outcome in Non-Small Cell Lung Cancer Clin. Cancer Res., April 15, 2005; 11(8): 2930 - 2936. [Abstract] [Full Text] [PDF]

				B. Ferraro, G. Bepler, S. Sharma, A. Cantor, and E. B. Haura EGR1 Predicts PTEN and Survival in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., March 20, 2005; 23(9): 1921 - 1926. [Abstract] [Full Text] [PDF]

				O. David, J. Jett, H. LeBeau, G. Dy, J. Hughes, M. Friedman, and A. R. Brody Phospho-Akt Overexpression in Non-Small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage Clin. Cancer Res., October 15, 2004; 10(20): 6865 - 6871. [Abstract] [Full Text] [PDF]

				X. Liao, L. Zhang, J. B. Thrasher, J. Du, and B. Li Glycogen synthase kinase-3{beta} suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer Mol. Cancer Ther., November 1, 2003; 2(11): 1215 - 1222. [Abstract] [Full Text] [PDF]

				T. R. Singh, S. Shankar, X. Chen, M. Asim, and R. K. Srivastava Synergistic Interactions of Chemotherapeutic Drugs and Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand on Apoptosis and on Regression of Breast Carcinoma in Vivo Cancer Res., September 1, 2003; 63(17): 5390 - 5400. [Abstract] [Full Text] [PDF]

				D. W. Kim, J. H. Hwang, J. M. Suh, H. Kim, J. H. Song, E. S. Hwang, I. Y. Hwang, K. C. Park, H. K. Chung, J. M. Kim, et al. RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinomas) Tyrosine Kinase Phosphorylates and Activates Phosphoinositide-Dependent Kinase 1 (PDK1): An Alternative Phosphatidylinositol 3-Kinase-Independent Pathway to Activate PDK1 Mol. Endocrinol., July 1, 2003; 17(7): 1382 - 1394. [Abstract] [Full Text] [PDF]

				F. H. Blackhall, M. Pintilie, M. Michael, N. Leighl, R. Feld, M.-S. Tsao, and F. A. Shepherd Expression and Prognostic Significance of Kit, Protein Kinase B, and Mitogen-activated Protein Kinase in Patients with Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2241 - 2247. [Abstract] [Full Text] [PDF]